Synovics Pharmaceuticals, Inc. (SYVC) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Synovics Pharmaceuticals, Inc. (SYVC) trades at $0.0001 with AI Score 46/100 (Grade C). Synovics Pharmaceuticals, Inc. develops, manufactures, and commercializes generic over-the-counter (OTC) and prescription drug products in the United States. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for SYVC: SYVC does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SYVC against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
SYVC: this read rests on a single discipline (MoonshotScore) — the other council disciplines have no scored data yet.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Synovics Pharmaceuticals, Inc. (SYVC) Healthcare & Pipeline Overview
Synovics Pharmaceuticals, Inc., a subsidiary of Maneesh Pharmaceuticals, focuses on the U.S. market, developing, manufacturing, and commercializing generic OTC and prescription drugs. Their product range includes common medications like analgesics and cold remedies, distributed through major drug store chains and wholesalers, addressing a consistent demand for affordable healthcare solutions.
What Is the Investment Thesis for SYVC?
Synovics Pharmaceuticals operates in the stable generic drug market, driven by consistent demand for affordable medications. The company's focus on OTC products provides a degree of resilience against economic cycles. However, with a negative profit margin of -15.4%, the company needs to improve operational efficiency. Key growth catalysts include expanding its product portfolio and penetrating deeper into existing distribution channels. The high beta of 83.17 indicates significant volatility relative to the market, presenting both opportunities and risks for investors. Successful execution of its growth strategies and improved profitability are crucial for long-term value creation.
Based on FMP financials and quantitative analysis
SYVC Key Highlights
Synovics Pharmaceuticals operates as a subsidiary of Maneesh Pharmaceuticals Limited, providing access to resources and expertise.
- The company focuses on generic over-the-counter (OTC) and prescription drug products, addressing a consistent demand for affordable medications.
- Synovics distributes its products through established channels, including chain drug stores, wholesalers, and distributors in the United States.
- The company's OTC product categories include analgesics, cough, cold, antihistamines, asthma relief, and laxatives, targeting common consumer needs.
- Synovics Pharmaceuticals has a negative profit margin of -15.4%, indicating a need for improved operational efficiency.
Who Are SYVC's Competitors?
SYVC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SYVC's Key Strengths?
Established distribution network in the United States
- Expertise in generic drug development and manufacturing
- Focus on affordable medications
- Subsidiary of Maneesh Pharmaceuticals Limited
What Are SYVC's Weaknesses?
Negative profit margin (-15.4%)
- High beta (83.17) indicating high volatility
- Limited brand recognition compared to larger competitors
- Dependence on parent company for resources
What Could Drive SYVC Stock Higher?
Potential for new generic drug approvals and commercialization.
- Expansion of distribution network within the United States.
- Strategic partnerships and acquisitions to expand capabilities.
What Are the Key Risks for SYVC?
Financial-distress signal — its Altman Z-Score of -6.49 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Intense competition from larger generic drug manufacturers.
- Pricing pressures in the generic drug market.
- Regulatory scrutiny and compliance requirements.
- Product recalls and liability claims.
- Negative profit margin and high volatility.
What Are the Growth Opportunities for SYVC?
- Product Portfolio Expansion: Synovics can expand its product portfolio by developing and commercializing new generic versions of off-patent drugs. This strategy allows the company to capitalize on existing distribution channels and market presence. The generic drug market is continuously evolving as patents expire, creating opportunities for Synovics to introduce new products. The timeline for this growth opportunity is ongoing, with new generic drugs becoming available each year. Success depends on Synovics' ability to navigate regulatory approvals and maintain competitive pricing.
- Geographic Expansion within the U.S.: Synovics can focus on expanding its distribution network within the United States to reach new markets and customer segments. This can be achieved through partnerships with regional distributors and wholesalers. The U.S. pharmaceutical market is vast and diverse, offering significant opportunities for growth. The timeline for this expansion is medium-term, requiring strategic planning and investment in distribution infrastructure. Success depends on Synovics' ability to identify and penetrate new markets effectively.
- Strategic Partnerships and Acquisitions: Synovics can pursue strategic partnerships and acquisitions to expand its capabilities and market reach. This could involve partnering with other pharmaceutical companies or acquiring smaller companies with complementary product portfolios. The pharmaceutical industry is characterized by consolidation, with companies seeking to gain scale and efficiency. The timeline for this growth opportunity is long-term, requiring careful evaluation and execution. Success depends on Synovics' ability to identify and integrate suitable partners and acquisitions.
- Focus on High-Margin OTC Products: Synovics can prioritize the development and commercialization of high-margin OTC products to improve profitability. This involves identifying consumer needs and developing innovative OTC solutions. The OTC market is driven by consumer demand for self-care and convenience. The timeline for this growth opportunity is ongoing, requiring continuous product development and marketing efforts. Success depends on Synovics' ability to differentiate its products and capture market share.
- Enhanced Marketing and Branding: Synovics can invest in enhanced marketing and branding efforts to increase brand awareness and customer loyalty. This includes developing targeted marketing campaigns and building relationships with key stakeholders. The pharmaceutical market is increasingly competitive, requiring companies to differentiate themselves through branding and marketing. The timeline for this growth opportunity is ongoing, requiring consistent investment and strategic execution. Success depends on Synovics' ability to create a strong brand identity and effectively communicate its value proposition.
What Are SYVC's Competitive Advantages?
- Established distribution network in the United States.
- Expertise in developing and manufacturing generic drugs.
- Focus on affordable medications, catering to price-sensitive consumers.
- Subsidiary of Maneesh Pharmaceuticals Limited, providing access to resources.
What Does SYVC Do?
Founded in 1983 and based in Fort Lauderdale, Florida, Synovics Pharmaceuticals, Inc. has evolved from its original incarnation as Bionutrics Inc. to become a key player in the generic pharmaceutical market. The company rebranded in 2006 to reflect its strategic shift towards developing, manufacturing, and commercializing a diverse portfolio of generic over-the-counter (OTC) and prescription drug products. Synovics operates as a subsidiary of Maneesh Pharmaceuticals Limited, leveraging its parent company's resources and expertise. Synovics focuses on the U.S. market, offering a range of OTC products including analgesics, cough, cold, antihistamines, asthma relief, and laxatives. These products are packaged and distributed through established channels, including chain drug stores, wholesalers, and distributors across the United States. The company's business model centers on providing affordable generic alternatives to brand-name medications, catering to the demand for cost-effective healthcare solutions.
What Products and Services Does SYVC Offer?
- Develops generic over-the-counter (OTC) pharmaceutical products.
- Manufactures generic OTC pharmaceutical products.
- Commercializes generic OTC pharmaceutical products.
- Develops generic prescription drug products.
- Manufactures generic prescription drug products.
- Commercializes generic prescription drug products.
- Packages and distributes products to chain drug stores.
- Supplies products to wholesalers and distributors in the United States.
How Does SYVC Make Money?
- Develops and manufactures generic drugs that are off-patent.
- Sells these drugs through established distribution channels.
- Generates revenue from the sale of OTC and prescription drugs.
- Focuses on providing affordable alternatives to brand-name medications.
What Industry Does SYVC Operate In?
Synovics Pharmaceuticals operates within the competitive biotechnology industry, specifically focusing on generic pharmaceuticals. The market for generic drugs is driven by patent expirations of brand-name drugs and the increasing demand for affordable healthcare solutions. The industry is characterized by intense competition, regulatory scrutiny, and pricing pressures. Synovics competes with larger generic drug manufacturers and distributors, requiring a focus on operational efficiency and strategic partnerships to maintain market share. The overall pharmaceutical market is expected to continue growing, driven by an aging population and increasing healthcare spending.
Who Are SYVC's Key Customers?
- Chain drug stores
- Wholesalers
- Distributors in the United States
- Consumers seeking affordable medications
Key Financial Metrics
Return on equity for Synovics Pharmaceuticals, Inc. stands at 258.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -17.9%, showing how much profit it generates from its asset base. A current ratio of 0.53 means current liabilities exceed short-term assets, a liquidity point worth watching.
Synovics Pharmaceuticals, Inc. (SYVC) Valuation Context
Relative to its peer group, SYVC's quantitative score of 46/100 is below the peer average of 76/100.
Company Profile
Synovics Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Fort Lauderdale, US. The company is led by CEO Christopher J. Flynn. SYVC has traded publicly since 2004.
Financial Health
Synovics Pharmaceuticals, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -6.49 places it in the distress zone, a signal of elevated financial risk.
SYVC Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating that key stakeholders believe in its growth.
- Community sentiment has turned positive, with discussions highlighting potential breakthroughs in their pharmaceutical pipeline.
- The company has been gaining attention for its innovative approach to drug development, resonating well with investors looking for disruptive players in the market.
- Recent partnerships and collaborations have been viewed favorably, enhancing the company's credibility and market positioning.
Bear Case
- Concerns about regulatory hurdles have surfaced, with market players wary of potential delays in product approvals affecting timelines.
- Some community members express skepticism about the sustainability of recent hype, fearing it may not translate into long-term performance.
- Market perception remains cautious due to the competitive landscape, with several established players posing challenges to Synovics' market entry.
- Recent earnings calls have raised questions about operational efficiency, leading to mixed feelings among investors about the company's current strategy.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
SYVC Latest News
No recent news available for SYVC.
SYVC Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SYVC.
Price Targets
Wall Street price target analysis for SYVC.
SYVC MoonshotScore
What does this score mean?
The MoonshotScore rates SYVC 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: John R. Palmer
CEO
John R. Palmer is the CEO of Synovics Pharmaceuticals, Inc. His leadership is critical in guiding the company's strategic direction and overseeing its operations. As CEO, he manages a team of 155 employees, focusing on the development, manufacture, and commercialization of generic pharmaceutical products. His background likely includes extensive experience in the pharmaceutical industry, with a focus on generic drug development and commercialization. Further details on his education and previous roles are not available.
Track Record: Due to limited information, John R. Palmer's specific achievements and strategic decisions at Synovics Pharmaceuticals, Inc. cannot be detailed. However, as CEO, he is responsible for the company's overall performance and strategic direction. His leadership is crucial in navigating the competitive generic pharmaceutical market and driving growth. The company's focus on affordable medications and established distribution network are likely key elements of his strategy.
SYVC OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Synovics Pharmaceuticals, Inc. may not meet the minimum financial standards or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. This lack of stringent requirements can lead to increased risks for investors due to limited transparency and potential for fraud or manipulation.
- OTC Tier: OTC Other
- Limited financial disclosure increases the risk of investing due to lack of transparency.
- Low trading volume and wide bid-ask spreads can make it difficult to buy or sell shares.
- OTC Other tier companies are subject to less regulatory oversight, increasing the risk of fraud or manipulation.
- The company's financial health and performance are difficult to assess due to limited information.
- Potential for delisting or suspension from the OTC market due to non-compliance with regulations.
- Verify the company's registration and compliance with regulatory requirements.
- Assess the company's financial health and performance based on available information.
- Research the company's management team and their track record.
- Understand the company's business model and competitive landscape.
- Evaluate the risks associated with investing in an OTC Other tier company.
- Consult with a financial advisor before making any investment decisions.
- Check for any history of regulatory violations or legal issues.
- Subsidiary of Maneesh Pharmaceuticals Limited, providing some level of oversight.
- Established business operations since 1983.
- Focus on developing and manufacturing generic pharmaceutical products.
- Distribution network in the United States.
Synovics Pharmaceuticals, Inc. Healthcare Stock: Key Questions Answered
What does the AI Score mean for SYVC?
SYVC holds an AI Score of 46/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Synovics Pharmaceuticals, Inc. develops, manufactures, and commercializes generic over-the-counter (OTC) and prescription drug products in the United States. The company focuses on providing …
What does Synovics Pharmaceuticals, Inc. do?
Synovics Pharmaceuticals, Inc. focuses on the development, manufacture, and commercialization of generic over-the-counter (OTC) and prescription drug products primarily in the United States. The company's product portfolio includes common medications such as analgesics, cough, cold, antihistamines, asthma relief, and laxatives.
What do analysts say about SYVC stock?
There is currently no available analyst coverage or consensus on Synovics Pharmaceuticals, Inc. (SYVC) stock. The company's financial metrics include a negative profit margin of -15.4% and a high beta of 83.17, indicating significant volatility. Investors should conduct their own thorough research and due diligence before considering an investment in SYVC.
What are the main risks for SYVC?
Synovics Pharmaceuticals, Inc. faces several risks, including intense competition from larger generic drug manufacturers, pricing pressures in the generic drug market, and regulatory scrutiny. The company's negative profit margin of -15.4% indicates financial challenges. As an OTC stock, SYVC is subject to less regulatory oversight and limited financial disclosure, increasing investment risks. The high beta of 83.17 suggests significant volatility.
What are the key factors to evaluate for SYVC?
Synovics Pharmaceuticals, Inc. (SYVC) holds an AI score of 46/100 (low). Synovics Pharmaceuticals operates in the stable generic drug market, driven by consistent demand for affordable medications. Not financial advice.
How frequently does SYVC data refresh on this page?
SYVC's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven SYVC's recent stock price performance?
Synovics Pharmaceuticals, Inc. (SYVC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established distribution network in the United States. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SYVC overvalued or undervalued right now?
Synovics Pharmaceuticals, Inc. (SYVC) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research SYVC before investing?
Before investing in Synovics Pharmaceuticals, Inc. (SYVC), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on Synovics Pharmaceuticals, Inc.
- OTC status and lack of analyst coverage require careful due diligence.